Read the full article at PR Newswire: Health
The Leading Information Source for Chronic Disease Research and Management
- Metabolic
- Cardiovascular
- Central Nervous System
- Respiratory
- Cancer
- Viral
- Industry News
- Gastrointestinal
- Blood Conditions
- Bone and Blood Conditions
- Lifestyle
- Osteoporosis
- Software
- General Message
- 2010
- 3SBio
- 800-847-6060
- A. Sidney Barritt
- ADL5747
- ADL5859
- ADVENTRX Pharmaceuticals
- AEterna Zentaris
- AG1000
- AG200-15
- AIDS
- ALS
- AMG 479
- ANA598
- AQX-1125
- ARN-509
- ARRY-162
- ASCO
- ASCO 2010
- ATX-101
- AVEO Pharmaceuticals
- AVI Biopharma
- Aaron Kowalski
- Aastrom Biosciences
- Abbie Celniker
- Abbott Labs
- Abraxis BioScience
- Abraxis Pharmaceutical
- Academic Medical Center
- Accentia Pharmaceuticals
- Achaogen
- Achillion Pharmaceuticals
- Acrux
- Actelion
- Actemra
- Actos
- Acura Pharmaceuticals
- Acurox
- Adam
- Adam Autona
- Adimab
- Adolor
- Adrian Adams
- AesRx
- Affimed Therapeutics
- Affymaxm
- Afrezza
- Africa
- Agile Therapeutics
- Agios Pharmaceuticals
- AiCuris
- Alain Froment
- Albany Molecular Research
- Albert Einstein College of Medicine
- Alcoholism
- Alectos
- Alexander Denner
- Alexion Pharmaceuticals
- Alexis Borisy
- Alimera Sciences
- Allan Bradley
- Allergan
- AlloCure
- Alnara Pharmaceuticals
- Alnylam Pharmaceuticals
- AlphaVax
- Alzheimer's
- Alzheimer's / Dementia
- Ambrx
- American Academy
- Amgen
- Amsterdam Molecular Therapeutics
- Amylin pharmaceuticals
- Amyris Biotechnologies
- Anacor Pharmaceuticals
- Anadys Pharmaceuticals
- Anchor Therapeutics
- Andrea Dunaif
- Andrew Witty
- Anika Therapeutics
- Ann Arbor
- Antares Pharma
- Antibiotics
- Antigenics
- Antonio Zorzano
- Anturol
- Apath
- Apexigen
- Aplastic Anemia
- April 2010
- Aptuit
- Aquinox
- ArQule
- Aradigm
- Aragon Pharmaceuticals
- Arcalyst
- Archimedes
- Arena Pharmaceuticals
- Ariad Pharmaceuticals
- Array BioPharma
- Arthritis / Rheumatology
- Aryx Therapeutics
- Ascenta Therapeutics
- Asia
- Assistant
- Astellas Pharma
- AstraZeneca
- Athens
- Athersys
- Aton Pharma
- August 2010
- Autoimmune Disease
- Avandia
- Avastin
- Avexa
- Avid Radiopharmaceuticals
- Avila Therapeutics
- Axanum
- BARDA
- BCX4208
- BD
- BIND Biosciences
- BIO
- BIO 2010
- BMI
- Barcelona
- Basilea Pharmaceutica
- Bayer Healthcare
- Bayer Schering
- Beate Ritz
- Becton, Dickinson and Company
- Belatacept
- Benlysta
- Beth Deaconess Medical Center
- Beth Israel
- Big Biotech
- Big Pharma
- Bill and Melinda Gates Foundation
- BioBAT
- BioMarin Pharmaceutical
- BioMerieux
- BioSante Pharmaceuticals
- BioScale
- Biocryst
- Biogen Idec
- Biologics
- Biology / Biochemistry
- Biomedicine
- Biotech CEO
- Biotech IPO
- Biotech Stock
- Biotech Venture Capital
- Biotech deals
- Biovail
- Bipolar
- Bisphosphonates
- Boehringer Ingelheim
- Bones / Orthopedics
- Boston
- Boston Red Sox
- BrainCells
- Brazil
- Breast Cancer
- Brian J. Zikmund-Fisher
- Brigham and Women's Hospital
- Brilinta
- Bristol-Myers Squibb
- Brown University
- Bruce Spiegelman
- Bruxelles
- Business
- Bydureon
- Byetta
- CGI Pharmaceuticals
- CHD
- CHS Pharma
- CK-1
- COPD
- CPEX Pharmaceuticals
- CRO
- CSL
- CXL-1020
- Cadence Pharmaceuticals
- California
- Calistoga Pharmaceuticals
- Calithera Biosciences
- Cambridge
- Campath
- Cancer / Oncology
- Cancer Drugs
- Cancer Prevention
- Cancer Research
- Cara Therapeutics
- Cardiome Pharma
- Cardiovascular / Cardiology
- Cardioxyl Pharmaceuticals
- Caribbean
- Carl Icahn
- Carlos Bustamante
- Carlos Museum
- Carlos Rodriguez
- Case Western Reserve University
- Catabasis Pharmaceuticals
- Catena
- CeNeRx BioPharma
- Celator Pharmaceuticals
- Celebrex
- Celgene
- Cell Therapeutics
- Celldex Therapeutics
- Cellerant Therapeutics
- Cellular Dynamics
- Centocor Ortho Biotech
- Ceplene
- Cerenis Therapeutics
- Cerezyme
- Chapel Hill
- Charles River
- Charles Wambebe
- ChemoFx
- Chicago
- Chicago Medical Center
- Chorus
- Chris Viehbacher
- Christian de Virgilio
- Christoph Westphal
- Christopher Benson
- Chulalongkorn University
- Chulalongkorn University, Bangkok
- Chutes and Ladders
- Cialis
- Cincinnati
- Cipla
- Ciprofloxacin
- City
- Clarus Ventures
- Clayton Foundation Laboratories
- Clayton Laboratories
- Cleveland Biolabs
- Clinical Medicine
- Clinical Trial
- Clinical Trial Results
- Clinical Trials / Drug Trials
- Clopidogrel
- Clovis Oncology
- Codexis
- Columbia
- Columbia University
- Columbia University Medical Center
- CombiMatrix
- Commission of European Communities
- Complete Genomics
- Concert Pharmaceuticals
- Conferences
- Conflict of interest
- Congress
- ConjuChem
- Connecticut
- Constellation Pharma
- Consulting
- Contrave
- Convulsions
- Copenhagen
- Coridon
- Cornell University
- Cornerstone Therapeutics
- Corticosteroids
- Covance
- Cowen Healthcare Royalty Partners
- Critical Path Initiative
- Cuba
- Cumberland Pharmaceuticals
- CureVac
- Curis
- Cushing's Syndrome
- Cypress Bioscience
- Cytheris
- Cytori Therapeutics
- Cytos Biotechnology
- D
- D. Redelmeier
- DNage
- Daiichi Sankyo
- Dainippon Sumitomo
- Dana
- David Barker
- David Packard
- Daxas
- Deaconess Medical Center
- Delcath
- Dendreon
- Dengue fever
- Denmark
- Denosumab
- Dentistry
- Depomed
- Development deals
- Diabetes
- Diabetes Care
- Diabetes Surgery Summit
- Diamyd
- Diana Kerwin
- Dicerna Pharmaceuticals
- Dickson Mounds
- Disaster
- Discovery Labs
- Dominican Republic
- Dong-Hoon Kim
- Donna M. Zulman
- Dov Lichtenberg
- Dov Pharmaceutical
- Dr. Patrick Soon-Shiong
- Dr. Steven Nissen
- Drotrecogin Alpha
- Drug Discovery
- Drug approvals
- Dublin
- Dulera
- Durect
- E. Lonn
- E5555
- EMEA
- EMEA Approval
- Economic development
- Edith King
- Edward Mascioli
- Efalizumab
- Effient
- Eisai
- Elan
- Eli Lilly
- Ella
- Emergent BioSolutions
- Emisphere
- Emory University
- Endo Pharmaceuticals
- Endocrinology
- Endocyte
- Entereg
- Entertainment
- Environment
- EpiCept
- Epitomics
- Eric Herlenius
- Ernest N. Morial
- Esme Fuller-Thomson
- Esophageal Cancer
- Euthymics Bioscience
- Eva Schernhammer
- Evan Snyder
- Eve A. Kerr
- Evotec
- Excelimmune
- Exelixis
- ExonHit Therapeutics
- Experimental Drugs
- Eye Health / Blindness
- FDA application process
- FDA approval
- FDA priority review
- FDA regulation
- FDA rejection
- FTY720
- Fatigue
- Featured
- February 2010
- Femta
- FerroKin Biosciences
- Finland
- Finnish Institute
- Finnish Institute of Occupational Health
- Florida
- Flutiform
- FoldRx Pharmaceuticals
- Food and Drug Administration
- Forecasting
- Forest Laboratories
- Foundation Medicine
- Fragile X Research
- France
- Francis Collins
- Francisco
- Frank Abboud
- Frank Anania
- GAINESVILLE
- GDC-0449
- GLG Pharma
- GPS
- GSK-299423
- GTC Biotherapeutics
- GTx
- GW Pharma
- Gail Donnelly
- Galapagos
- Gardasil
- Gemin X Pharmaceuticals
- Gen-Probe
- GenMab
- Genentech
- General Electric
- Generic Biologics
- Genetics
- Genocea Biosciences
- Genomics Institute
- Genvec
- Genzyme
- George Armelagos
- George Scangos
- Georgia
- Geron
- Gestiva
- Gilead Sciences
- Gilenia
- GlaxoSmithKline
- Glenmark Pharmaceuticals
- Global
- GlobeImmune
- Glumetza
- Gomberg
- Google Ventures
- Gordon McInnes
- Graduate School
- Grazax
- Greek Organisation Against Drugs
- Grifols
- Gustavo Saposnik
- H1N1
- HCV
- HCV RNA
- HCV treatment
- HIV/AIDS
- HRA Pharma
- Hall F
- Harold Hines Jr.
- Harvard
- Hasbro
- Hawaii Biotech
- Health Insurance / Medical Insurance
- Healthcare Ventures
- Helicos BioSciences
- Helixis
- Helsinki
- HemaQuest Pharmaceuticals
- Hematide
- Hemispherx Biopharma
- Henri Termeer
- Hepatitis C
- Hong Lu
- Horizant
- Horizon Therapeutics
- Hospira
- Human Genome Sciences
- Human Interest
- Huntington's Disease
- Hypertension Treatment
- IK-1001
- INC Research
- INO-8875
- INX-189
- IT / Internet / E-mail
- Igenica
- Ikaria
- Illinois
- Illumina
- Iluvien
- Ilya Pinchuk
- Imatinib Mesylate
- Immune Design
- ImmunoCellular Therapeutics
- ImmunoGen
- ImmunoSolv
- Incline Therapeutics
- Incyte Corporation
- Infections
- Infectious Diseases
- Infectious Diseases / Bacteria / Viruses
- Infinity Pharmaceuticals
- Inhibitex
- Inotek Pharmaceuticals
- Inspire Pharmaceuticals
- Insulin
- Intellikine
- Intercell
- Intermune
- Ionsys
- Iowa
- Ipsen
- Ireland
- Ironwood Pharmaceuticals
- Isis Pharmaceuticals
- Island Hospital
- Isoniazid
- Isotechnika
- Israel
- Italy
- Itero Biopharmaceuticals
- J. Carver Biomedical Chair
- J. Craig Venter
- JDRF JDRF
- JZP-6
- James Mullen
- James Wright
- Jan van de Winkel
- Janine Galone
- Janssen
- January 2010
- Japan
- Javelin Pharmaceuticals
- Jazz Pharmaceuticals
- Jean-Marie Bodo
- Jeff Williamson
- Jennifer G. Robinson
- Joel Ray
- John Fitzpatrick
- John Lechleiter
- John Nolan
- John Wiley Sons
- Johnson Johnson
- Jolla
- Jonas Salk
- Jorge R. Oksenberg
- Jorgen Olsen
- Jose Carlos Gutierrez-Ramos
- July 2010
- June 2010
- KNS-760704
- KV Pharmaceutical
- Karen L. Margolis
- Karo Bio
- Katarzyna Bryca
- Keryx Biopharmaceuticals
- Kevin Fiscella
- Kidney Diseases
- Kineta
- King Pharmaceuticals
- Kissei Pharmaceutical
- Knome
- Knopp Neurosciences
- Kymab
- Kythera Biopharmaceuticals
- Labor
- Lambda Canada
- Lansing
- Latin America
- Law
- Lei Qian
- Lewis H. Kuller
- Lewis Kuller
- Licensing deals
- Life Technologies
- Lillian R. Meacham
- Linaclotide
- LipimetiX
- Lisa Drakeman
- Liver Disease / Hepatitis
- Liver Fibrosis
- Liver transplant
- Lobbying
- Logical Therapeutics
- London
- Los Angeles
- Lou Gehrig's disease
- Lovenox
- Loxoprofen
- Lucile Packard
- Lung Disease
- Lycera
- MBX-2982
- MDD PROVIDENCE
- MDRNA
- MGI Pharma
- MK-4305
- MRC Technology
- MRI
- MRSA
- Magnetic Resonance Imaging
- Mannkind
- Mapatumumab
- March 2010
- Marco Prado
- Mardi Gomberg-Maitland
- Margaret Hamburg
- Marian Limacher
- Marianna Virtanen
- Marie B. Gale
- Marina
- Mark Chapleau
- Mark O. Huising
- Mark Zimmerman
- Market Access
- Market Research
- Marketing
- Marshall Edwards
- Martin Mackay
- Mary Ellen Michele Heisler
- Maryland
- Massachusetts
- Massachusetts Biotechnology Council
- Mater Misericordiae University Hospital
- Matthew R. Nelson
- May 2010
- Mayo Clinic
- MedImmune
- Medical College of Wisconsin, Milwaukee
- Medical Device
- Medical Devices / Diagnostics
- Medicines for Malaria Venture
- Medtronic
- Melanoma
- Memorial Hospital
- Mepact
- Merck
- Merck KgAA
- Merck Serono
- Mergers and Acquisitions
- Mersana Therapeutics
- Mesoblast
- Metabasis Therapeutics
- Metabolex
- Metabolic Control
- Metabolic Disturbances
- Metabolic Research Group
- Metabolix
- Metoclopramide
- Mexico
- Michael Welsh
- Michigan
- Michigan Agricultural Experiment Station
- Michigan State University
- MiddleBrook Pharmaceuticals
- Mikael Dolsten
- Millennium Pharmaceuticals
- Millipore
- Milwaukee
- Minneapolis
- Minnesota
- Mirina Corporation
- Molecular and Cellular Biology
- Molly Rosen Chair
- Montefiore Medical Center
- Moshe Leshno
- Movetis
- Multiple Sclerosis
- Myriad Genetics
- Myriad Pharmaceuticals
- NDM-1
- NICE
- NME approvals
- NOV-002
- NSF update
- NVC-422
- Nastech
- National Cancer Institute
- National Institute of Health
- National Institutes of Health
- National Science Foundation
- Nautilus Neurosciences
- Nektar Therapeutics
- Nereus Pharmaceuticals
- Neupogen
- NeurogesX
- Neurological Disorders
- Neurology / Neuroscience
- Neuroscience
- New England
- New Jersey
- New Orleans
- New York
- New York City
- Newron
- NiCox
- Niacin
- Nick R. Bryan
- Nigeria
- Nivestim
- NormOxys
- North Carolina
- Northwestern
- Northwestern University
- NovImmune
- NovaBay Pharmaceuticals
- Novagali
- Novartis
- Novelos
- Novo Nordisk
- Noxxon pharma
- Nupathe
- Nutrition / Diet
- Nycomed
- OSI Pharmaceuticals
- Obesity / Weight Loss / Fitness
- Ofirmev
- Olanzapine
- Olga Anagnostou
- Olympus IS-10 Film Camera
- Omid Farokhzad
- OncoMed Pharmaceuticals
- Oncology
- Online Marketing
- Ontario
- Onyx Pharmaceuticals
- OptiNose
- Oracle
- Oralair
- Orexigen Therapeutics
- Orexo
- Osteonecrosis
- Otonomy
- PI3-K
- PITTSBURGH
- PLX-PAD
- PLX4032
- PPAR-g
- PPD
- PRA International
- PRX302
- Pacific Biosciences
- Pain / Anesthetics
- Paris
- Patients
- Patricia Kilian
- Pearson Chair
- PecFent
- Pediatrics / Children's Health
- Penelope
- Pennsylvania
- Penwest Pharmaceuticals
- Perifosine
- Pervasis Therapeutics
- Pfizer
- Pharma Strategy
- Pharmaceutical Sales and Marketing
- Pharmasset
- Pharmathene
- Pharming
- Phase Forward
- Phase I
- Phenomix Corporation
- Philadelphia
- Pixantrone
- Plexxikon
- Pluristem Technology
- Polio
- PolyTherics
- Portola Pharmaceuticals
- Posidur
- Poxel
- Pozen
- Pradaxa
- Precision Therapeutics
- PregLem
- Pregabalin
- Pregnancy / Obstetrics
- Primary Care / General Practice
- Proceedings of the National Academy of Sciences
- Program
- Progressive Multifocal Leukoencephalopathy
- Prolia
- Propofol
- Prostate / Prostate Cancer
- Protalix
- Protox Therapeutics
- Provenge
- Providence
- Proximagen Neuroscience
- Psychology / Psychiatry
- Puerto Rico
- Pulmonary Hypertension
- Pyramax
- Qnexa
- Quaker Bioventures
- Quark Pharmaceuticals
- Quebec
- Questions and Answers
- Quetiapine
- Quintiles
- R&D
- R&D budget
- R&D spending
- RNAi
- Radiology / Nuclear Medicine
- Ramius
- Ranbaxy
- Randy Seeley
- Raptor Pharmaceutical
- Rash
- ReSearch Pharmaceutical Services
- Reading
- Reading Campus
- Reata Pharmaceuticals
- Recentin
- Regeneration
- Regeneron Pharmaceuticals
- Regulation
- Regulus Therapeutics
- Renal Failure
- Repros
- Research
- RespiVert
- Respiratory / Asthma
- Response Genetics
- Restless Legs Syndrome
- Retacrit
- Revimmune
- Rezulin
- Rhabdomyolysis
- Rheumatoid Arthritis
- Rhode Island
- Rhode Island Hospital
- Rhucin
- Ricardo Azziz
- Richard L. Sidman
- Rifampicin
- Robert Farese
- Robert Gros
- Robert Langer
- Robert V. Farese
- Robert Wood Johnson
- Roche
- Rochester
- Rochester Medical Center
- Roger D. Soloway
- Roman Hovorka
- Roux-en-Y
- Rubino
- SEATTLE
- SFE Strategy
- STX-100
- SV Life Sciences Advisers
- Sales
- San Diego
- San Francisco
- Sandoz
- Sanford-Burnham
- Sangamo BioSciences
- Sanjiv Shah
- Sanofi-Aventis
- Santarus
- Santhera
- Sarah A. Gaussoin
- Sarah A. Jaramillo
- Sarah Tishkoff
- Saskatchewan
- Sativex
- Schering-Plough
- Scotland
- Scott Williams
- Seattle Genetics
- Selecta Biosciences
- Seniors / Aging
- Sepracor
- Severin Schwan
- Shannon L. Rhodes
- Shin Poong Pharmaceutical
- Shionogi
- Shire Pharmaceuticals
- Sigma Pharmaceuticals
- Silvia Guatimosim
- Simvastatin
- Sinai
- Sinai Medical Center
- Singapore
- Sirtris Pharmaceuticals
- SkyePharma
- Sleep / Sleep Disorders / Insomnia
- Social Issues
- Social Media
- Sombat Treeprasertsuk
- Sonus Pharmaceuticals
- Soren Friis
- South America
- Spain
- SparVax
- Sports Medicine / Fitness
- Stallergenes
- Stedesa
- Stem Cell Research
- Stem Cell Therapeutics
- Stempeutics
- Stephen L. Archer
- Stephen L. Hauser
- Stephen Woods
- Steve Kaldor
- Steve Reed
- Steven Burrill
- Steven Quay
- Stimuvax
- Stroke
- Stromedix
- Stuart Rich
- Suneil Koliwad
- Supply Chain
- Surfaxin
- Susan Molineaux
- Susanne Mohr
- Sweden
- Swine Flu
- Sylvia Wassertheil-Smoller
- Synthetic biology
- T-DM1
- TL011
- TRU-015
- TTP399
- Takeda
- Talecris Biotherapeutics
- Taligen Therapeutics
- Tardive Dyskinesia
- TargeGen
- Technology
- Teklamo
- Tekturna
- Tel-Aviv University
- Tempero Pharmaceuticals
- Tesaro
- TetraLogic
- Tetraphase Pharmaceuticals
- Teva Pharmaceutical Industries
- Texas
- Texas A&M
- Thailand
- Thenappan Thenappan
- Therapeutic Discovery Credit
- Theratechnologies
- Thessaloniki
- Third Rock Ventures
- This week's bedtime reading
- Thrombocytopenia
- Tibotec
- Timothy P. Hofer
- Tinzaparin
- Topical Anesthetics
- Topiramate
- Toronto
- TransTech
- Transdermal patches
- Transition Therapeutics
- Transplantation
- Transplants / Organ Donations
- Trastuzumab-DM1
- Trevena
- Trinity College Dublin
- Trius Therapeutics
- Trophos
- Trubion Pharmaceuticals
- U.S. Centers for Disease Control and Prevention
- U.S. Department of Health and Human Services
- U.S. Food and Drug Administration
- U.S. News World Report
- UCB
- UCLA
- UCLA Medical Center
- USD
- United Kingdom
- United States
- University College London
- University Hospital
- University Medical Center
- University deal
- University of California, San Francisco
- University of Cincinnati
- University of Florida
- University of Iowa
- University of North Carolina
- University of Pennsylvania
- University of Pennsylvania, Philadelphia
- University of Pittsburgh
- University of Pittsburgh Graduate School
- University of Rochester
- University of Texas Medical Branch
- University of Toronto
- University of Western Ontario
- Urology / Nephrology
- VR315
- VX-770
- Vaccine
- Valeant Pharmaceuticals
- Vanderbilt University
- Vania Prado
- Varenicline
- Vascular
- Vatican
- Vaximm
- Vectura Group
- Venrock Associates
- Venture Capital fund
- Vernalis
- Vicept
- Victory Pharma
- Viiv
- Virtual model
- Vitamin E
- Vivus
- WINSTON-SALEM
- Wake Forest University
- Warfarin
- Water – Air Quality / Agriculture
- Watson Pharmaceuticals
- Weather
- Weight loss pills
- Wellcome Trust Clinical Research Facility
- West Coast
- Wilex
- William T Lowrance
- Wisconsin
- WuXi
- Wylie Vale
- XL184
- XMT-1107
- Xarelto
- Xenoport
- Xiamen Innovax Biotech
- Yaacov Drory
- Yariv Gerber
- Yedidya (Didi) Dotan
- Yeshiva University
- Yeshiva University Albert Einstein College of Medicine
- Zalbin
- Zogenix
- Zonisamide
- adjuvant
- adult stem cells
- alogliptin
- amputation
- amyloid beta
- animal rights activists
- animal testing
- antibiotic
- apixaban
- apoptosis
- arrhythmia
- arthritis
- atherosclerosis
- australia
- autism
- avanafil
- back pain
- bacterial infection
- bankruptcy
- bapineuzumab
- bariatric surgery
- biodefense
- biomarkers
- biosimilar
- biotech insider trading
- biotech investing
- biotech jobs
- biotech patent news
- biotech tax credit
- birth control
- blindness
- blood glucose
- boceprevir
- body mass index
- brain cancer
- cabazitaxel
- calcitonin
- cambridge massachusetts
- canada
- cancer care
- cancer therapeutics
- cancer vaccine
- cancers
- cardiac disease
- cardiac hypertrophy
- cardiovascular disease
- ceftobiprole
- chemical
- china
- cholangitis
- cholestasis
- cholesterol
- chronic
- chronic HCV infection
- cirrhosis
- cladribine
- collaborations
- colorectal cancer
- coma
- connective tissue disease
- contraceptive
- coronary disease
- coronary heart disease
- crizotinib
- cysts
- danoprevir
- darapladib
- diabetes outside
- diabetic retinopathy
- diagnostics
- disease
- donepezil
- drug delivery technology
- drug development
- drug discovery technologies
- drug prices
- drug therapies
- drug therapy
- dutogliptin
- earnings
- elagolix
- elinogrel
- embryonic stem cells
- emerging markets
- emerging outsourcing trends
- endometriosis
- energy
- epidemic
- epidemics
- eprotirome
- erectile dysfunction
- eribulin
- europe
- expert advice
- fatty liver
- febit
- female sexual dysfunction
- flibanserin
- flu vaccine
- food
- funding
- gallstone
- gallstones
- gastric by-pass surgery
- gastrointestinal surgery
- gene therapy
- genomics
- genotype
- glucose intolerance
- gout
- health
- healthcare
- healthcare reform
- heart attack
- heart attacks
- heart disease
- hepatitis B
- hepatitis E
- hepatocellular carcinoma
- high blood pressure
- high cholesterol
- hirsutism
- hormone therapy
- hypoactive sexual desire disorder
- hypoglycemia
- iPieran
- imaging
- immunization
- india
- infectious disease
- infertility
- inflammation
- innovative therapies
- insomnia
- insulin delivery
- insulin injections
- insulin pump
- insulin resistance
- insulin therapy
- invasive procedures
- ipilimumab
- isavuconazole
- job cuts
- kidney cancer
- kidney disease
- kidney failure
- l-arginine
- lactose intolerance
- laparoscopic surgery
- layoffs
- legislation
- liprotamase
- liver disease
- liver transplants
- lixisenatide
- lorcaserin
- low blood pressure
- low-fat diets
- lung cancer
- lupus
- major depressive disorder
- malaria
- manufacturing
- marizomib
- medical records
- metabolic disorder
- metabolic disorders
- milestones
- mipomersen
- molecular diagnostics
- monoclonal antibody
- motavizumab
- multiple myeloma
- muscle weakness
- muscular dystrophy
- myocardial infarction
- myocardial infarctions
- nanotechnology
- naproxcinod
- necrosis
- neurocrine biosciences
- neurodegenerative disorder
- neurosurgery
- obatoclax
- ocrelizumab
- ofatumumab
- orphan drug status
- outsourcing
- ovarian cancer
- ovarian cysts
- p53 biomarker
- pain
- pain therapy
- pancreatic cancer
- pancreatitis
- partnership
- patent expiration
- peroxisome proliferator-activated receptor
- pharmacogenomic
- phenoxodiol
- pipeline
- pirfenidone
- plinabulin
- polycystic ovary syndrome
- preclinical
- procedures
- proellex
- prostate cancer
- radiation
- radiation treatment
- rare diseases
- regenerative medicine
- regorafenib
- renal cancer
- renal cell carcinoma
- restructuring
- resuscitation
- resveratrol
- ridaforolimus
- rivaroxaban
- sales and marketing
- salsalate
- savella
- science
- seizures
- sequencing
- series c
- shortness of breath
- sickness
- skin cancer
- small molecules
- spin-off
- spinal cord injuries
- statins
- stem cells
- sub-Saharan Africa
- surgery
- tanezumab
- taspoglutide
- telaprevir
- telemedicine
- tesamorelin
- the 2009 Outstanding Scientific Achievement Award
- the American College
- the American Journal
- the European Heart Journal
- the European Respiratory Journal
- the Proceedings of the National Academy of Sciences
- the University of Chicago
- the University of Iowa
- the University of Michigan
- the University of Pennsylvania
- toremifene
- total body irradiation
- translational research
- transparency
- treatment of cancer
- trends
- tumor
- type 2 diabetes
- ulipristal
- ultrasound
- undefined
- vaccines
- vascular disease
- vernakalant
- vertex
- vipadenant
- vitamin D
- vitamin D deficiency
- vitamin deficiency
- west Africa
- workforce expansion
- zalutumumab
- zibotentan
Home
General
Oxford Finance Corporation Provides $5 Million Revolving Line of Credit to Avanti Health System, LLC
General
Oxford Finance Corporation Provides $5 Million Revolving Line of Credit to Avanti Health System, LLC
Oxford Finance Corporation Provides $5 Million Revolving Line of Credit to Avanti Health System, LLC
Posted on Tuesday, 24 August 2010 by PR Newswire: Health
ALEXANDRIA, Va., Aug. 24 /PRNewswire/ -- Oxford Finance Corporation, a subsidiary of Sumitomo Corporation, today announced that it closed a $5 million revolving line of credit agreement with Avanti Health System, LLC and its affiliate CHHP Holdings II, LLC. The group, which owns and operates acute c
Share this Post:
Tagged with:
Leave a Reply:
Event & News Updates
Sign up to receive breaking news as well as receive other site updates!
Our Sponsors
Recent Posts
- Cord Blood America Reports that Umbilical Cord Blood Stem Cells Are Now Being Used in Experimental Effort to Treat Type 1 Diabetes
- Increase In Physician Referrals Could Lead To Increase In Health Care Costs
- High-Cost Screening Instead Of More Effective Tests Usually Offered To Neuropathy Patients
- Saliva Test Could Replace Blood Test For Diabetics
- Nurturing Mothers Rear Physically Healthier Adults
Sources
- A Word from Kathryn
- Diabetes News From Medical News Today
- DiabetesMine: the all things diabetes blog
- Eat Renal-Friendly, with June Martin
- Endocrine Metabolic Medical Center Blog
- eyeforpharma.com | Pharma strategy for the busy executive -
- FierceBiotech
- Gibbs Biomedical Consulting
- Pharmacovigilance
- PhysioGenix blogs
- PR Newswire: Biotechnology
- PR Newswire: Clinical Trials & Medical Discoveries
- PR Newswire: Health
- Renal BizBlog – Keith Chartier
- Renal Business News Only Feed
- Renal Business Today Articles
- renal tsar’s blog
- ScienceBlog.com – diabetes
- ScienceBlog.com – hypertension
Recent Posts
- Cord Blood America Reports that Umbilical Cord Blood Stem Cells Are Now Being Used in Experimental Effort to Treat Type 1 Diabetes
- Increase In Physician Referrals Could Lead To Increase In Health Care Costs
- High-Cost Screening Instead Of More Effective Tests Usually Offered To Neuropathy Patients
- Saliva Test Could Replace Blood Test For Diabetics
- Nurturing Mothers Rear Physically Healthier Adults
Archives
About Author
The Chronicus post is the one place on the internet to find all news stories, blog publications, and personal articles relating to chronic diseases and management.
We launched in December of 2009, and hope to build a community of authors and sources to bring the best to the people who are affected by chronic diseases.